Vancouver, BC, and Ottawa, ON (November 15, 2021) – adMare BioInnovations is pleased to announce a collaboration with the University of Ottawa to bring new resources and focus to the…
Read More
Vancouver, BC and Charlottetown, PEI (November 9, 2021) – adMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership…
MONTREAL, Quebec – November 2, 2021: District 3 Innovation Hub, an early-stage startup incubator located at Concordia University, and adMare BioInnovations, a Canadian life sciences leader that builds the industry…
Charlottetown, P.E.I. (October 21, 2021) – BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex…
The company and its partners have secured CAD$1 million to apply and improve MFI’s virtual drug-design software in support of preclinical research targeting antibiotic-resistant bacteria and non-alcoholic fatty liver disease…
MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL)…
LAVAL, Quebec–(BUSINESS WIRE)–Sep. 13, 2021– BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related…
A new made-in-Canada life sciences company, NIMIUM Therapeutics, has been launched to develop novel therapies for patients with cardiometabolic diseases. The company’s foundational technology is based on the cutting-edge research…
Over the past few months, adMare BioInnovations and the Centre for Probe Development and Commercialization (CPDC) have shared with you information about the role and the potential of radiopharmaceuticals in…
adMare BioInnovations (“adMare”) and AazeinTx Inc. (“AazeinTx”) have closed a global exclusive licensing transaction for a promising acute asthma treatment. Under the agreement, AazeinTx has acquired all rights to NEO6860,…
